Surmodics (Nasdaq:SRDX) announced today that it commercially launched the Pounce XL thrombectomy system for clot removal.
Pounce XL joins the larger suite of Pounce thrombectomy systems. They offer rapid endovascular removal of acute or chronic clot from peripheral arteries.
Eden Prairie, Minnesota-based Surmodics designed Pounce to enable physicians to rapidly restore blood flow regardless of clot morphology. Its fully mechanical thrombectomy devices can promptly remove organized thrombus or embolus. They don’t require thrombolytics, aspiration, or capital equipment.
Nitinol innovation: Download our free special report featuring nitinol expertise and tips from medical device OEMs
Surmodics describes Pounce systems as “grab-and-go” solutions, deployable and simple to use. Each system features a delivery catheter, a basket wire and a funnel catheter. The basket wire deploys two nitinol self-expanding baskets, which capture the clot before retracting into the nitinol collection funnel. With the clot entrained, the system withdraws into a guide sheath, which removes the clot from the body.
The Pounce XL received FDA 510(k) clearance in September 2024. Surmodics kicked off a limited market release of the system with the first early clinical use in February.
“The addition of the Pounce XL Thrombectomy System fulfills our vision of providing a simple, effective platform for removing peripheral arterial blood clots throughout the leg,” said Gary Maharaj, Surmodics president and CEO. “When minutes matter, physicians appreciate the availability of a readily deployable solution with a track record of dependable and safe results. We’re proud of the growing clinical adoption of this product and the benefits it is bringing to limb ischemia patients in need of urgent care.”
